News
Bactolife secures over €30m in Series B funding to commercialise

Gut health solutions company Bactolife has successfully raised over €30 million in its Series B investment round.
The funding will enable the company to commercialise its innovative Binding Proteins, a new food, feed and dietary supplement ingredient, and execute its human study programme, aimed at transforming human and animal health for proactive health management.
This significant financing round was led by Cross Border Impact Ventures (CBIV) and EIFO (Danish Export and Investment Fund), alongside continued support from existing investors Novo Holdings and Athos.
With the backing of cornerstone investors, Bactolife is now poised to launch its first Binding Protein products under the ingredient brand, Helm for human health in the United States in 2026.
The company plans to expand into Asia and Europe in the years that follow, with a strong commitment to ensuring the technology is accessible to women and children in low- and middle-income countries (LMICs).
Sebastian Søderberg, CEO of Bactolife, said: “Today’s successful close of our Series B round sets the stage for exciting years ahead as we prepare to launch our innovative products in 2026.
“This funding will enable us to clinically validate, scale, and commercialise our Binding Proteins, taking Bactolife’s solutions to a broad audience.
“We are excited to welcome new investors to the Bactolife family and are deeply grateful to our existing investors, whose continued support reflects their confidence in our mission.
“We are ready to transform gut health with novel Binding Proteins.”
The proceeds from this round will be directed toward several key areas of growth for Bactolife, including the execution of its human study program across the US, EU, Asia, and LMICs.
In addition, the company plans to scale its manufacturing and supply operations to meet global demand with a strong emphasis on commercialisation of both human and animal health ingredients for dietary supplements, functional food and beverages, and feed additives.
Donna Parr, Managing Partner at Cross Border Impact Ventures, said: “We are thrilled to lead Bactolife’s Series B. Bactolife’s Binding Proteins have the potential to strengthen gut resilience for mothers and children in low- and middle-income countries by providing a scalable, food-grade solution that can be integrated into everyday nutrition.
“At the same time, we are excited about the significant growth opportunity across North America, Europe, and Asia where the market opportunity is massive.
“This investment reflects our conviction that evidence-based technologies can reach massive high-growth markets, inclusive of people who need them most, and we look forward to partnering with Bactolife to accelerate clinical validation, scale manufacturing, and expand equitable access globally.”
Diagnosis
AI may help accelerate breast cancer diagnosis for high-risk women – study
Fertility
Infertility may be risk factor for early menopause, study suggests
pain conditions
Endometriosis documentary profiles stars including Marilyn Monroe and Amy Schumer

A non-profit has launched an endometriosis documentary featuring Amy Schumer and Marilyn Monroe as it pushes for changes in how the condition is treated and understood.
The Endometriosis Collective has launched to change how endometriosis is researched, treated and understood, starting with a documentary featuring stories from people including Amy Schumer and Marilyn Monroe.
The feature-length documentary, “End of the Cycle”, will premiere in New York on Tuesday, and The Endometriosis Collective is making the film free to stream online.
Schumer, a comedian, writer and actor, has previously spoken of how endometriosis left her “on the floor in pain, vomiting from the pain, the pain that nobody can see.”
Schumer is one of several celebrities featured in the documentary. Other contributors include dancer Julianne Hough, Olympic medallist Brittany Brown and actors Janel Parrish and Folake Olowofoyeku.
The Endometriosis Collective timed the documentary premiere to coincide with the 100th anniversary of Marilyn Monroe’s birth.
Monroe, who died in 1962, starred in films such as “Some Like It Hot” and “Gentlemen Prefer Blondes.”
According to a biography published in 1985, Monroe’s endometriosis was so severe that it destroyed her marriages, her wish for children, her career and ultimately her life.
The Endometriosis Collective said the documentary shares newly uncovered information about Monroe’s experience with endometriosis.
The non-profit said the information connects Monroe’s story to the experiences of women across generations, highlighting how far awareness, research and care still have to go.
A representative of the Marilyn Monroe Estate said: “By sharing this part of her story through ‘End of the Cycle,’ we hope to honour her legacy in a way that brings visibility to endometriosis, encourages more open dialogue and helps inspire the research needed to create change.”
As part of the premiere, The Endometriosis Collective is holding a panel discussion.
Schumer, Brown and Olowofoyeku, the documentary’s co-directors Sammy Jaye and Soraya Simi, and medical experts are due to be part of the premiere.
AbbVie’s Orilissa and Sumitomo Pharma’s Myfembree are among the approved drugs for endometriosis pain.
Hough, one of the participants in the documentary, starred in an Orilissa campaign in 2017.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Wellness4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Hormonal health2 weeks agoNHS urged to update website following renaming of PCOS
News6 days agoThree menopause innovators shortlisted for Femtech World Award
















1 Comment